ENVB Stock Risk & Deep Value Analysis

Enveric Biosciences Inc

DVR Score

5.0

out of 10

Proceed with Caution

What You Need to Know About ENVB Stock

We analyzed Enveric Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ENVB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Apr 23, 2026•Run Fresh Analysis →

ENVB Risk Analysis & Red Flags

What Could Go Wrong

The company's extremely limited cash runway (approximately 2.5 quarters after the latest raise) and high quarterly burn rate mean it will need significant additional capital very soon. If this funding is secured through highly dilutive means, or if it cannot be secured on favorable terms, existing shareholder value could be further eroded dramatically, potentially leading to a substantial stock price decline or even delisting.

Risk Matrix

Overall

Aggressive

Financial

High

Market

Medium

Competitive

Medium

Execution

High

Regulatory

High

Red Flags

⚠
Persistent, high cash burn with critically limited cash runway.
⚠
Continuous, significant share dilution to fund operations, severely impacting per-share value.
⚠
Net loss widened from Q4 prior year to Q4 2025.
⚠
Extremely low market capitalization ($0.01B) for a pre-clinical biotech, reflecting market distress.

Upcoming Risk Events

📅
Q1 2026 earnings revealing increased cash burn or shorter runway
📅
Announcement of another highly dilutive financing round
📅
Negative or inconclusive preclinical/clinical data for lead candidates
📅
Regulatory setbacks for IND application

When to Reconsider

🚪
Announcement of another highly dilutive capital raise (e.g., >30% dilution or priced significantly below current market).
🚪
Failure to secure IND for EB-003 within the next 12-18 months.
🚪
Cash balance drops below one quarter of operating expenses without new, secured funding.

Unlock ENVB Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Enveric Biosciences represents a highly speculative, high-risk, high-reward investment focused on its innovative EVOC platform developing neuroplastogenic small molecules for significant CNS disorders. Despite severe financial distress and continuous share dilution, the recent patent approval and positive preclinical data for EB-003 provide a foundation of intrinsic asset value. The investment thesis hinges on the company's ability to advance its pipeline to key clinical milestones and, crucially, secure non-dilutive partnerships or licensing deals that can fund development and validate its technology, potentially leading to a re-rating of its deeply discounted market valuation.

Is ENVB Stock Undervalued?

Enveric Biosciences operates in a massive CNS market with a promising, differentiated psychedelic/cannabinoid-inspired platform (EVOC) and strengthening IP through a recent patent for its EVM301 series, including positive preclinical data for EB-003. This scientific progress offers significant therapeutic potential and future optionality. However, the company faces severe financial challenges, characterized by a high cash burn rate (net loss widened to $4.0M in Q4 2025) and critically limited cash runway (approximately 2.5 quarters after recent $5M raise). Persistent and significant share dilution, including a recent private placement at $2.25 per share and prior raises, continues to severely undermine the path to 10x *share price* growth, despite potential asset appreciation. While catalysts exist in pipeline progression and potential licensing, the aggressive dilution and poor financial health make substantial per-share returns highly improbable, aligning with previous 'dud' classification for multi-bagger stock appreciation, albeit with slight improvement due to confirmed IP and preclinical data.

Unlock the full AI analysis for ENVB

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

ENVB Price Targets & Strategy

12-Month Target

$4.50

Bull Case

$7.00

Bear Case

$1.50

Valuation Basis

Projected value of pre-clinical pipeline assets (EB-003) offset by ongoing cash burn and assumed dilutive financing needs for next 12 months.

Entry Strategy

Consider small allocation near current levels ($3.00-$3.60). A stronger entry point would be around the recent private placement price of $2.25 if the stock retests that level due to further dilution.

Exit Strategy

Take 50% profit on any significant rallies above $6.00. Implement a stop-loss order around $2.00 to protect capital from further dilution or negative clinical news.

Portfolio Allocation

1-3% for aggressive risk tolerance

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is ENVB Financially Healthy?

Valuation

P/E Ratio

-0.30

Price/Book

0.60

Profitability

Gross Margin

20.42%

Operating Margin

-15.88%

Net Margin

-14.05%

Return on Equity

-349.10%

Revenue Growth

-7.16%

EPS

$-89.80

Balance Sheet

Current Ratio

1.84

Quick Ratio

1.50

Total Debt

$920,000

Cash & Equivalents

$4.68M

Other

Beta (Volatility)

1.05

Does ENVB Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

1 Identified

Intangible Assets/IP (Patents on EVOC platform and specific drug candidates like EVM301/EB-003)

The moat's durability is moderate and hinges entirely on the validity, breadth, and enforceability of its patent portfolio, coupled with the successful clinical progression of its drug candidates. Without clinical validation, the IP alone offers limited commercial protection against well-funded competitors.

Moat Erosion Risks

•Patent challenges or expiration, reducing proprietary protection.
•Failure of lead drug candidates (e.g., EB-003) in clinical trials.
•Faster or more effective drug development by larger, better-funded competitors.
•Limited resources to defend IP or expand the pipeline.

ENVB Competitive Moat Analysis

ENVB Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral (Likely mixed sentiment among retail investors, with long-term believers in the science offset by frustration over dilution).

Institutional Sentiment

Neutral (No analyst ratings or significant institutional activity reported; likely very low institutional ownership given the company's size, stage, and financial instability).

Insider Activity (Form 4)

No Form 4 filings reported in the last 90 days (Jan 23 - Apr 23, 2026).

Options Flow

Normal options activity (No specific unusual options activity or significant directional bias reported in the provided data).

Earnings Intelligence

Next Earnings

Estimated early May 2026 (for Q1 2026)

Surprise Probability

Low

Historical Earnings Pattern

Not enough historical data to establish a consistent pattern, but the stock is likely to be highly volatile around significant news related to funding or clinical milestones, rather than routine quarterly financial reports which typically show losses.

Key Metrics to Watch

Updated cash balance and cash burn rateUpdates on preclinical/clinical pipeline progress (e.g., EB-003 IND submission)Commentary on future financing plans and runway

Competitive Position

Top Competitor

ATAI Life Sciences (ATAI)

Market Share Trend

N/A (Pre-commercial biotech)

Valuation vs Peers

ENVB's market capitalization ($0.01B) is significantly lower than more advanced psychedelic/neuro-biotech peers like ATAI Life Sciences (>$100M), reflecting its earlier pipeline stage and more precarious financial position. It could be seen as deeply undervalued if its preclinical assets achieve clinical validation and non-dilutive funding, but currently reflects extreme risk.

Competitive Advantages

•Proprietary EVOC (Enveric's Psychedelics-Inspired and Cannabinoid-Derived Small Molecules) platform for drug discovery.
•Growing intellectual property portfolio, including recent patent for EVM301 series (EB-003).
•Differentiated mechanism of action for lead candidates targeting 5-HT2A/5-HT1B for CNS disorders.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive ENVB Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated early May 2026)
•Further positive preclinical data for EVM301/EB-003
•Potential Investigational New Drug (IND) filing for EB-003

Medium-Term (6-18 months)

•Initiation of Phase 1 clinical trial for EB-003
•Announcement of strategic partnership or licensing deal for a pipeline asset
•Advancement of other EVOC platform candidates

Long-Term (18+ months)

•Phase 2 clinical data readout for EB-003
•Significant expansion of proprietary EVOC platform and IP portfolio
•Industry disruption from novel neuroplastogenics

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for ENVB?

✓
Successful progression of EB-003 to IND filing and into Phase 1 clinical trials.
✓
Securing a significant non-dilutive licensing or partnership agreement for any pipeline asset.
✓
Any substantial improvement in cash burn rate or securing of sustained, less dilutive funding sources.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

How Enveric Biosciences Inc Makes Money

Enveric Biosciences is a preclinical-stage biotechnology company that aims to discover and develop novel, orally-available small molecules inspired by psychedelics and cannabinoids for the treatment of central nervous system (CNS) disorders such as depression, PTSD, and anxiety. The company currently does not generate revenue. Its business model focuses on leveraging its proprietary 'EVOC' drug discovery platform to create new chemical entities, protect them with patents, and then advance these candidates through preclinical testing. The ultimate goal is to out-license these assets to larger pharmaceutical companies for further clinical development and commercialization, or to advance them through clinical trials itself, generating revenue from milestone payments, royalties on future sales, or eventual direct product sales.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Enveric Biosciences Inc (ENVB)?

As of April 23, 2026, Enveric Biosciences Inc has a DVR Score of 5.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Enveric Biosciences Inc?

Enveric Biosciences Inc's market capitalization is approximately $6.8M..

What is the risk level for ENVB stock?

Our analysis rates Enveric Biosciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of ENVB?

Enveric Biosciences Inc currently has a price-to-earnings (P/E) ratio of -0.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Enveric Biosciences Inc's revenue growing?

Enveric Biosciences Inc has reported revenue growth of -7.2%. Revenue has been declining, which warrants closer examination.

Is ENVB stock profitable?

Enveric Biosciences Inc has a profit margin of -14.1%. The company is currently unprofitable.

How often is the ENVB DVR analysis updated?

Our AI-powered analysis of Enveric Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 23, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ENVB (Enveric Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.